Last reviewed · How we verify
NCT06873360
Medical Device for Oxaliplatin-Induced Neuropathy in Gastrointestinal Cancer Patients
trial testing Clinical interviews with patients and Usability interviews and glove testing. in Peripheral Neuropathy Due to Chemotherapy in 50 participants. Completed in 30 December 2025.
30 November 2025
Quick facts
| Lead sponsor | Corporacion Parc Tauli |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 50 |
| Start date | 1 April 2025 |
| Primary completion | 30 November 2025 |
| Estimated completion | 30 December 2025 |
| Sites | 1 location across Spain |
Drugs / interventions tested
- Clinical interviews with patients and Usability interviews and glove testing.
Conditions studied
- Peripheral Neuropathy Due to Chemotherapy — all drugs for Peripheral Neuropathy Due to Chemotherapy →
Sponsor
Corporacion Parc Tauli — full company profile →
Who can join
18 and older, any sex, with Peripheral Neuropathy Due to Chemotherapy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is an observational study related to a medical device designed for the prevention of oxaliplatin-induced peripheral neuropathy (OIPN) in patients with gastrointestinal cancer. The primary objective is to collect data through interviews with patients experiencing OIPN symptoms to co-design the medical device prototype, incorporating the patient's perspective. Additionally, the study aims to identify clinical and usability patterns that will help optimize the design of a future clinical investigation assessing the safety and efficacy of the final device.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06873360
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Peripheral Neuropathy Due to Chemotherapy
Currently open trials in the same condition.
- NCT07423390 — Study on the Efficacy and Safety of Mecobalamin in Preventing Taxane-related Peripheral Neuropathy · Phase 3 · recruiting
- NCT06807294 — Feasibility Testing of a Tai Chi Program for Chemotherapy-Induced Peripheral Neuropathy Treatment (TCT) · NA · recruiting
- NCT06744816 — Exploring the Benefit of Topical Capsaicin in Treating Pain From Chemo-induced Peripheral Neuropathy: a Longitudinal Sin · EARLY_PHASE1 · recruiting
- NCT07167446 — Neuroprotective Potential of Cannabidiol (CBD) in Preventing Oxaliplatin (Ox)-Induced Neuropathy · EARLY_PHASE1 · recruiting
- NCT06616649 — Closed Loop Spinal Cord Stimulation for Chemotherapy Induced Peripheral Neuropathy, a Pilot Study. · NA · recruiting
Other Corporacion Parc Tauli trials
Trials by the same sponsor.
- NCT07331805 — Conservative Management in Primary Spontaneous Pneumothorax: a Multicenter Randomized Non-inferiority Study · NA · not yet recruiting
- NCT06900335 — Functional Connectome in Prader-Willi Syndrome: Neuroimaging and AI to Assess Therapeutic Impact · completed
- NCT06511700 — Implementation of the Intravitreal Injection Administered by Nurses · enrolling by invitation
- NCT07298720 — Assessing Fluid-responsiveness Using Non-invasive Hybrid Diffuse Optics on Peripheral Muscle · recruiting
- NCT06603831 — Clinical Evaluation and Cost-effectiveness Analysis of 3D Digital Surgery in Traumatology · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06873360 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Corporacion Parc Tauli
- Last refreshed: 10 March 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06873360.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing